March 28, 2018 / 5:11 AM / 6 months ago

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

March 28 (Reuters) - IPSEN SA:

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

* ‍FILING BASED ON GLOBAL PLACEBO-CONTROLLED PHASE 3 TRIAL RESULTS WHICH MET PRIMARY ENDPOINT OF OVERALL SURVIVAL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below